Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Nov 1: Mercks blockbuster Keytruda racked up another FDA approval Wednesday, as the company announced that the anti-PD-1 therapy is now authorizedin combination with gemcitabine and cisplatinto treat patients with locally advanced unresectable or metastatic biliary tract cancer (BTC)
Consequently, chronic exposure to oxidants conditions cellular metabolism by oxidizing lipids
Energy failure and abnormal mitochondrial dynamics are central components of ischemic injury [8]
Buyers should verify expiration dates before completing purchases
US$ 29.10
US$ 25.51
US$ 26.58
US$ 29.90
